Friday, July 17, 2026 Home
Startup Atlas · Artificial Intelligence

NIRAMAI Health Analytix

Niramai Health Analytix Private Limited Bengaluru, Karnataka Founded 2016 niramai.com ↗
Geetha Manjunath · Founder & CEO Nidhi Mathur · Co-founder
$6 MnTotal funding (tracked)
2Funding rounds
25 Feb 2019Last round

NIRAMAI Health Analytix: Business Model Canvas

The nine-block Business Model Canvas, filled in only where a public source states it — empty blocks mean we haven't found a citable fact yet, not that the answer is zero.

Value Propositions

Non-invasive, radiation-free early detection

Thermalytix aims to detect breast cancer earlier without the radiation exposure of mammography, addressing late-stage detection as a key cause of breast cancer deaths.

source
Company-reported accuracy gains over mammography27% higher accuracy than mammography (company-reported trial results)

NIRAMAI cites clinical trial results showing higher accuracy and predictive value than mammography and standard thermography interpretation.

source
Effective for dense breast tissue

Addresses a known gap where standard X-ray mammography underperforms.

source
FDA-cleared device usable by general healthcare personnel

SMILE-100 System received US FDA clearance, allowing healthcare personnel (not just radiologists) to review and analyze thermal breast images.

source

Customer Segments

Hospitals & multi-specialty diagnostic chainsApollo Clinic partner

Deploys Thermalytix screening through tie-ups with hospital and diagnostic chains such as Apollo Clinic.

source
State public health systems

Government health departments contract NIRAMAI for population-level screening programs, e.g. Punjab's Department of Health & Family Welfare.

source
Women with dense breast tissue underserved by mammography

Targets women for whom traditional X-ray mammography is less effective, particularly those with dense breast tissue.

source

Customer Relationships

No cited public information yet.

Channels

Hospital & diagnostic chain tie-ups

Reaches patients by partnering with existing hospital and diagnostic chains rather than only selling direct.

source
Government-run population screening camps

Distributes screening at scale through state government health department programs, e.g. the Punjab 'Pink project'.

source

Key Activities

Clinical trials & peer-reviewed validation

Runs clinical studies to validate Thermalytix accuracy and publishes results in peer-reviewed journals and conferences.

source
Running large-scale government screening programs

Operates population-level screening drives in partnership with state health departments.

source

Key Resources

Thermalytix AI/ML diagnostic engine + thermal sensing device

Core proprietary product combining a high-resolution thermal sensing device with a cloud-hosted AI/ML analytics engine.

source
ML infrastructure on Google Kubernetes Engine

Runs nine machine learning models in production via containerized deployment.

source
US FDA-cleared SMILE-100 System

Regulatory clearance for its breast thermography device broadens the resource base for commercial deployment in the US.

source

Key Partnerships

Google Cloud

Runs its ML models and screening application on Google Kubernetes Engine and Firebase for scalability.

source
Government of Punjab (Dept. of Health & Family Welfare) & Roche Products India

Three-way partnership to deliver statewide AI-enabled breast cancer screening in Punjab.

source
Apollo Clinic (Apollo Health & Lifestyle)

Tie-up to offer contactless breast cancer screening through Apollo's clinic network.

source
CDC Group / British International Investment

UK development finance institution provided research funding for NIRAMAI's COVID-era FeverTest screening pilot.

source

Revenue Streams

No cited public information yet.

Cost Structure

No cited public information yet.

FAQs on NIRAMAI Health Analytix

What is NIRAMAI Health Analytix's business model?

NIRAMAI Health Analytix's core value proposition centers on Non-invasive, radiation-free early detection, Company-reported accuracy gains over mammography, Effective for dense breast tissue, FDA-cleared device usable by general healthcare personnel.

Sources & corrections. Every fact on this page is compiled from cited public sources — follow the “source” links beside each entry. Profile sources: cloud.google.com · Last verified 18 Jul 2026. · Report a correction